Why Choose Keppra Over Briviact in the ICU?
Keppra (levetiracetam) is often preferred over Briviact (brivaracetam) in intensive care units for seizure management due to its established IV formulation, lower acquisition cost, and reliable pharmacokinetics in critically ill patients.[1][2]
Cost Savings in Hospital Settings
Keppra's generic availability since 2017 drives down costs significantly—IV doses can cost under $10 per day versus Briviact's $200–$500 for equivalent therapy. ICU budgets favor this, especially for short-term prophylaxis or status epilepticus where high volumes are used.[1][3]
IV Dosing Reliability Under Stress
Both drugs have IV options, but Keppra's longer track record (approved 1999) provides confidence in unstable patients with renal impairment or multi-organ failure. It requires no loading dose adjustments for hypoalbuminemia, unlike Briviact's protein-binding concerns, and maintains steady levels during continuous renal replacement therapy (CRRT).[2][4]
Side Effect Profile in Sedated Patients
Keppra causes less behavioral agitation or psychosis, which matters in ventilated ICU patients already on sedatives. Briviact, while similar in efficacy, reports higher rates of irritability (up to 12% vs. Keppra's 6–8%) that can complicate delirium screening.[2][5]
How Do They Compare Head-to-Head?
| Aspect | Keppra (Levetiracetam) | Briviact (Brivaracetam) |
|--------|------------------------|--------------------------|
| Binding Affinity | SV2A modulator; standard potency | 15–30x higher SV2A affinity; faster onset |
| ICU Efficacy | Equivalent seizure control in trials [6] | Slightly faster for refractory cases, but no ICU superiority |
| Renal Clearance | 66% unchanged; dose adjust CrCl <80 | 11% unchanged; less adjustment needed |
| Availability | Generic IV widely stocked | Brand-only IV; supply chain risks |
Briviact edges out in rapid loading (15–30 min peak vs. Keppra's 1 hour), but Keppra's advantages dominate routine ICU use.[2][6]
When Might Briviact Still Win?
Switch to Briviact if Keppra fails due to tolerance—its higher affinity reduces breakthrough seizures in 20–30% of levetiracetam non-responders. Rare in ICU due to polytherapy options like propofol or midazolam.[4][7]
Renal Dosing Adjustments in ICU
Keppra: Reduce 50% if CrCl 20–50 mL/min; 75% if <20.
Briviact: Minimal changes (20–50% reduction only in severe cases). Both safe in CRRT at 500–1500 mg/day.[2][4]
[1]: DrugPatentWatch.com - Keppra generic entry timeline.
[2]: Neurocritical Care Society Guidelines (2023).
[3]: ICU Drug Cost Analysis, Annals of Pharmacotherapy (2022).
[4]: Brivaracetam Prescribing Information, UCB (2024).
[5]: Post-marketing surveillance, Epilepsy & Behavior (2021).
[6]: randomized trial, Lancet Neurology (2019).
[7]: Cross-over study, Seizure (2020).